Journal of Neurology

, Volume 257, Supplement 2, pp 309–313 | Cite as

Evidence-based initiation of dopaminergic therapy in Parkinson's disease



The mainstay of Parkinson's disease (PD) therapy is levodopa. The crucial question is when should levodopa be initiated? Levodopa provides the most potent motor benefit for PD, but longer term use is marked by the development of motor complications such as fluctuations in response and involuntary motor movements. Dopamine agonists reduce the risk of development of motor complications in the 5-year term. However, side effects may change the risk-benefit of dopamine agonist first strategies. In the following, the evidence for levodopa and dopamine agonists as initial monotherapy for PD is examined.


Parkinson disease Initiation of therapy Evidence-based practice Dopamine agonists Levodopa 


  1. 1.
    Adams RN, Murrill E, McCreery R, Blank L, Karolczak M (1972) 6-Hydroxydopamine a new oxidation mechanism. Eur J Pharmacol 17:287–292CrossRefPubMedGoogle Scholar
  2. 2.
    American Psychiatric Association (2000) Diagnostic and statistical manual of mental ‘disorders, fourth edition (DSM-IV-TR). American Psychiatric Publishing, Washington, DCCrossRefGoogle Scholar
  3. 3.
    Clement MV, Long LH, Ramalingam J, Halliwell B (2002) The cytotoxicity of dopamine may be an artefact of cell culture. J Neurochem 81:414–421CrossRefPubMedGoogle Scholar
  4. 4.
    de Bie R, Miyasaki J, Lang AE, Fox SH (2007) Clinical practice regarding dopamine-agonist use and driving in Parkinson’s disease. Can J Neurol Sci 34:438–442PubMedGoogle Scholar
  5. 5.
    Du F, Qian ZM, Zhu L, Wu XM, Yung WH, Tsim TY, Ke Y (2009) l-DOPA neurotoxicity is mediated by up-regulation of DMT1-IRE expression. PloS ONE (Electronic Resource) 4(2):e4593CrossRefGoogle Scholar
  6. 6.
    Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A, Olanow CW, Tanner C, Marek K, Parkinson Study Group (2004) Levodopa and the progression of Parkinson's disease. NEJM 351(24):2498–2508CrossRefPubMedGoogle Scholar
  7. 7.
    Giladi N, Weitzman N, Schreiber S, Shabtai H, Peretz C (2007) New onset heightened interest or drive for gambling, shopping, eating or sexual activity in patients with Parkinson’s disease: the role of dopamine agonis treatment and age at motor symptoms onset. J Psychopharmacol 21(5):501–506CrossRefPubMedGoogle Scholar
  8. 8.
    Gjerstad MD, Alves G, Wentzel-Larsen T, Aarsland D, Larsen JP (2006) Excessive daytime sleepiness in Parkinson's disease: is it the drugs or the disease? Neuorlogy 67(5):853–858CrossRefGoogle Scholar
  9. 9.
    Graham DG (1978) Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinines. Mol Pharmacol 14:633–643PubMedGoogle Scholar
  10. 10.
    Hobson DE, Lang AE, Martin WR, Razmy A, Rivest J, Fleming J (2002) Excessive daytime sleepiness and sudden-onset sleep in Parkinson's disease: a survey by the Canadian movement disorders group. JAMA 287:255–263CrossRefGoogle Scholar
  11. 11.
    Katzenschlager R, Head J, Schrag A, Ben-Shlomo Y, Evans A, Lees AJ, Parkinson’s disease research group of the United Kingdom (2008) Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology 71:474–480CrossRefPubMedGoogle Scholar
  12. 12.
    Kim HJ, Park SY, Cho YJ, Hong KS, Cho JY, Seo SY, Lee DH, Jeon BS (2009) Nonmotor symptoms in de novo Parkinson's disease before and after dopaminergic treatment. J Neurol Sci 15(287):200–204CrossRefGoogle Scholar
  13. 13.
    Kostic V, Przedborski S, Flaster MS, Stemic N (1991) Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson’s disease. Neurology 41:202–205PubMedGoogle Scholar
  14. 14.
    Marin C, Aguilar E, Mengod G, Cortes R, Obeso JA (2009) Effects of early vs late initiation of levodopa treatment in hemiparkinsonian rats. Eur J Neurosci 30:823–832CrossRefPubMedGoogle Scholar
  15. 15.
    Marras C, Lang A, Krahn M, Tomlinson G, Naglie G (2004) Quality of life in early Parkinson’s disease: impact of dyskinesias and motor fluctuations. Mov Disord 19:22–28CrossRefPubMedGoogle Scholar
  16. 16.
    Mena MA, Casarejos MJ, Carazo A, Paino CL, Garcia de Yebenes J (1997) Glia protect fetal midbrain dopamine neurons in culture from l-DOPA toxicity through multiple mechanisms. J Neural Transm 104:317–328CrossRefPubMedGoogle Scholar
  17. 17.
    Miyasaki JM, Martin W, Suchowersky O, Weiner WJ, Lang AE (2002) Practice parameter: initiation of treatment for Parkinson’s disease—an evidence-based review. Neurology 58:11–17PubMedGoogle Scholar
  18. 18.
    Montel S, Bonnet AM, Bungener C (2009) Quality of life inr elation to mood, coping strategies and dyskinesia in Parkinson’s disease. J Geriatr Psychiatry Neurol 22:95–102CrossRefPubMedGoogle Scholar
  19. 19.
    Nair VD, Olanow CW, Sealfon SC (2003) Activation of phosphoinositide 3-kinase by D2 receptor prevents apoptosis in dopaminergic cell lines. Biochem J 373:25–32CrossRefPubMedGoogle Scholar
  20. 20.
    Owen AD, Schapira AH, Jenner P, Marsden CD (1996) Oxidative stress and Parkinson’s disease. Ann N Y Acad Sci 786:217–233CrossRefPubMedGoogle Scholar
  21. 21.
    Parkinson study group CALM cohort investigators (2009) Long-term effect of initiating pramipexole vs levodopa in early Parkinson's disease. Arch Neurol 66:563–570CrossRefGoogle Scholar
  22. 22.
    Parkinson study group (2002) Pramipexole versus levodopa as initial treatment for Parkinson’s disease. JAMA 284:1931–1938CrossRefGoogle Scholar
  23. 23.
    Parkinson study group (2000) Beta CIT-SPECT assessment of progression of Parkinson’s disease in subjects participating in the CALM-PD study. Neurology 54:A90Google Scholar
  24. 24.
    Parkinson study group (2002) Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson's disease progression. JAMA 287:1653–1661CrossRefGoogle Scholar
  25. 25.
    Paus S, Brecht HM, Koster J, Seeger G, Klockgether T, Wullner U (2003) Sleep attacks, daytime sleepiness and dopamine agonists in Parkinson’s disease. Mov Disord 18:659–667CrossRefPubMedGoogle Scholar
  26. 26.
    Qin Z, Zhang L, Sun F, Fang X, Meng C, Tanner C, Chan P, The Chinese Parkinson study group (2009) Health related quality of life in early Parkinson’s disease: impact of motor and non-motor symptoms, results from Chinese levodopa exposed cohort. Parkinsonism Relat Disord 15:767–771CrossRefPubMedGoogle Scholar
  27. 27.
    Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE (2000) A 5-year study of dyskinesias in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. NEJM 342:1484–1491CrossRefPubMedGoogle Scholar
  28. 28.
    Suzuki K, Miyamoto T, Miyamoto M, Okuma Y, Hattori N, Kamei S, Yoshii F, Utsumi H, Iwasaki YM, Iijima M, Hirata K (2008) Excessive daytime sleepiness and sleep episodes in Japanese patients with Parkinson’s disease. J Neurol Sci 271:47–52CrossRefPubMedGoogle Scholar
  29. 29.
    Tanaka M, Sotomatsu A, Kanai H, Hirai S (1991) Dopa and dopamine cause cultured neuronal death in the presence of iron. J Neurol Sci 101:198–203CrossRefPubMedGoogle Scholar
  30. 30.
    van Rooden SM, Visser M, Verbaan, Marinus J, van Hilten JJ (2009) Patterns of motor and non-motor features in Parkinson’s disease. J Neurol Neurosurg Psychiatry 80:846–850CrossRefPubMedGoogle Scholar
  31. 31.
    Voon V, Hassan K, Zurowski M, de Souza M, Thomsen T, Fox S, Lang AE, Miyasaki J (2006) Prevalence of repetitive and reward-seeking behaviors in parkinson disease. Neurology 67:1254–1257CrossRefPubMedGoogle Scholar
  32. 32.
    Webster DD (1969) Quantitative measurements of l-dopa therapy in Parkinson’s disease. Trans Am Neurol Assoc 94:348–350PubMedGoogle Scholar
  33. 33.
    Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy MA, Whetteckey J, Wunderlich GR, Lang AE (2008) Mov Disord 23(S1)PosterGoogle Scholar

Copyright information

© Springer-Verlag 2010

Authors and Affiliations

  1. 1.The Movement Disorders Centre, Toronto Western HospitalUniversity Health NetworkTorontoCanada

Personalised recommendations